Literature DB >> 3541600

Induction of acute corneal allograft rejection by alpha-2 interferon.

A D Jacobs, J E Levenson, D W Golde.   

Abstract

A 38-year-old man who underwent corneal transplantation in 1973 for treatment of a keratoconus is described. In 1982, hairy cell leukemia was diagnosed and he was treated with splenectomy followed by chlorambucil and androgen therapy. In April 1984, treatment with alpha-2 interferon was begun, and two weeks later, evidence of acute corneal allograft rejection developed. The allograft rejection responded to temporary discontinuation of alpha-interferon and the administration of topical corticosteroid. Treatment with interferon was resumed, and he has subsequently had no clinical evidence of rejection. Although the mechanism of antineoplastic activity of alpha-interferon in hairy cell leukemia is unknown, the observations described in this report suggest that clinically important immune phenomena may occur in patients undergoing interferon therapy.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3541600     DOI: 10.1016/0002-9343(87)90405-0

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  2 in total

1.  DDX58(RIG-I)-related disease is associated with tissue-specific interferon pathway activation.

Authors:  Lev Prasov; Brenda L Bohnsack; Antonette S El Husny; Lam C Tsoi; Bin Guan; J Michelle Kahlenberg; Edmundo Almeida; Haitao Wang; Edward W Cowen; Adriana A De Jesus; Priyam Jani; Allison C Billi; Sayoko E Moroi; Rachael Wasikowski; Izabela Almeida; Luciana N Almeida; Fernando Kok; Sarah J Garnai; Shahzad I Mian; Marcus Y Chen; Blake M Warner; Carlos R Ferreira; Raphaela Goldbach-Mansky; Sun Hur; Brian P Brooks; Julia E Richards; Robert B Hufnagel; Johann E Gudjonsson
Journal:  J Med Genet       Date:  2021-01-25       Impact factor: 6.318

Review 2.  Ocular toxicity of systemic anticancer chemotherapy.

Authors:  Afekhide Ernest Omoti; Caroline Edijana Omoti
Journal:  Pharm Pract (Granada)       Date:  2006-04
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.